Trevi Therapeutics (TRVI) – Analysts’ Weekly Ratings Changes

Posted by Cynthia Vaughn on Mar 31st, 2025

A number of firms have modified their ratings and price targets on shares of Trevi Therapeutics (NASDAQ: TRVI) recently:

3/19/2025 – Trevi Therapeutics had its “buy” rating reaffirmed by analysts at B. Riley. They now have a $20.00 price target on the stock, up previously from $11.00.
3/19/2025 – Trevi Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $12.50 price target on the stock.
3/19/2025 – Trevi Therapeutics had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $21.00 price target on the stock.
3/19/2025 – Trevi Therapeutics had its price target lowered by analysts at Needham & Company LLC from $25.00 to $24.00. They now have a “buy” rating on the stock.
3/11/2025 – Trevi Therapeutics had its price target raised by analysts at Oppenheimer Holdings Inc. from $12.00 to $20.00. They now have an “outperform” rating on the stock.
3/10/2025 – Trevi Therapeutics was upgraded by analysts at Raymond James from an “outperform” rating to a “strong-buy” rating. They now have a $29.00 price target on the stock, up previously from $9.00.
3/10/2025 – Trevi Therapeutics had its price target raised by analysts at HC Wainwright from $7.50 to $12.50. They now have a “buy” rating on the stock.
3/10/2025 – Trevi Therapeutics had its price target raised by analysts at Needham & Company LLC from $8.00 to $25.00. They now have a “buy” rating on the stock.
3/7/2025 – Trevi Therapeutics had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $21.00 price target on the stock.
2/24/2025 – Trevi Therapeutics had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $21.00 price target on the stock.

Trevi Therapeutics Stock Performance

Shares of TRVI opened at $6.50 on Monday. The business’s fifty day moving average price is $4.87 and its two-hundred day moving average price is $3.88. The firm has a market capitalization of $628.43 million, a price-to-earnings ratio of -14.77 and a beta of 0.90. Trevi Therapeutics, Inc. has a 52 week low of $2.30 and a 52 week high of $7.39.

Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) last announced its quarterly earnings data on Tuesday, March 18th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.01. As a group, research analysts forecast that Trevi Therapeutics, Inc. will post -0.49 EPS for the current year.

Insider Transactions at Trevi Therapeutics

In other Trevi Therapeutics news, insider Farrell Simon sold 81,313 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $6.75, for a total value of $548,862.75. Following the transaction, the insider now directly owns 76,900 shares of the company’s stock, valued at approximately $519,075. This trade represents a 51.39 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jennifer L. Good sold 5,263 shares of the company’s stock in a transaction on Friday, March 21st. The shares were sold at an average price of $6.58, for a total transaction of $34,630.54. Following the sale, the chief executive officer now owns 213,313 shares of the company’s stock, valued at $1,403,599.54. The trade was a 2.41 % decrease in their position. The disclosure for this sale can be found here. 24.37% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Trevi Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. increased its stake in shares of Trevi Therapeutics by 220.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 100,517 shares of the company’s stock valued at $336,000 after acquiring an additional 69,167 shares during the last quarter. Geode Capital Management LLC raised its holdings in Trevi Therapeutics by 10.2% in the third quarter. Geode Capital Management LLC now owns 1,264,166 shares of the company’s stock worth $4,223,000 after purchasing an additional 117,418 shares during the period. Barclays PLC raised its holdings in Trevi Therapeutics by 180.8% in the third quarter. Barclays PLC now owns 95,232 shares of the company’s stock worth $319,000 after purchasing an additional 61,317 shares during the period. State Street Corp boosted its position in shares of Trevi Therapeutics by 5.9% during the third quarter. State Street Corp now owns 952,912 shares of the company’s stock worth $3,183,000 after purchasing an additional 53,051 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in shares of Trevi Therapeutics by 2.1% in the 4th quarter. Bank of New York Mellon Corp now owns 140,219 shares of the company’s stock valued at $578,000 after buying an additional 2,935 shares during the period. Institutional investors own 95.76% of the company’s stock.

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.